The Emergence of a Highly Mutated COVID Threat
A novel and highly mutated COVID-19 variant, colloquially named 'cicada,' is now circulating in at least 25 states across the United States. This concerning strain, scientifically designated as BA.3.2, possesses an extraordinary number of genetic alterations that may enable it to bypass immunity from both prior infections and existing vaccines.
Unprecedented Spike Protein Mutations
The cicada variant's spike protein—the critical component targeted by vaccines—has accumulated approximately 75 distinct mutations. This substantial genetic overhaul makes the variant appear almost entirely foreign to immune systems previously exposed to other COVID strains. While national COVID case numbers remain relatively low, public health authorities are monitoring this variant's steady expansion both domestically and internationally.
BA.3.2 initially emerged over a year ago but remained relatively dormant until autumn 2025, when it began surging in multiple countries including the United States. COVID variants naturally mutate as they spread through populations, acquiring new genomic alterations that can sometimes result in more severe disease outcomes.
Symptom Profile and Emerging Concerns
The symptoms associated with the cicada variant mirror those of other COVID strains. According to the Centers for Disease Control and Prevention, these include:
- Runny or stuffy nose
- Fever and headache
- Fatigue and sneezing
- Sore throat and cough
- Muscle aches and digestive issues
- Loss or alteration of smell and taste
Some newer variants have also been linked to an extremely painful condition informally termed 'razorblade throat.' While there is no definitive evidence that the cicada variant causes more severe illness, experts express concern that its novel nature leaves American immune systems potentially unprepared for a possible spring surge.
Global Monitoring and Designation
In December 2025, the World Health Organization designated BA.3.2 as a 'variant under monitoring' due to its concerning mutation profile. The nickname 'cicada' originates from Dr. T. Ryan Gregory, an evolutionary biology professor at Canada's University of Guelph, who has previously coined other variant names including 'stratus' and 'pirola.'
The variant first infected individuals in South Africa during late 2024. After being temporarily overshadowed by other strains, it resurged approximately one year later, reaching American shores. While not currently dominant in the United States—where the XFG omicron sub-lineage prevails—BA.3.2 accounts for roughly 30 percent of cases in Denmark, Germany, and the Netherlands.
Tracking the Variant's Spread
According to CDC wastewater surveillance data from the week ending March 21, BA.3.2 now represents approximately 11 percent of circulating COVID variants nationally. The variant first arrived in the United States on June 27, 2025, when a traveler from the Netherlands tested positive at San Francisco International Airport.
Wastewater detection in Rhode Island during November 2025 preceded clinical cases by several months. The first confirmed patients emerged in early January 2026: two hospitalized older adults with underlying health conditions and one young child, all of whom recovered successfully.
By February 2026, the variant had been identified in international travelers, clinical patients, and over 130 wastewater samples spanning two dozen states. The CDC employs three primary surveillance systems:
- National laboratory testing networks
- Airport screening of international travelers including voluntary nasal swabs and airplane wastewater analysis
- A nationwide wastewater surveillance system monitoring approximately 1,450 sewer sites
These systems detected BA.3.2's arrival months before hospitalizations occurred. When samples are identified, scientists analyze genetic codes, compare them to current vaccines using specialized software, and construct evolutionary trees to understand strain relationships.
Vaccine Effectiveness and Public Health Guidance
The latest COVID vaccine formulated for the 2025-2026 season demonstrates strong effectiveness against the currently dominant JN.1 strains. However, laboratory testing against seven variants revealed its weakest performance against BA.3.2, suggesting potentially reduced protection—though real-world data remains necessary for conclusive assessment.
Importantly, while BA.3.2 appears adept at evading immunity, current vaccines still provide substantial protection against severe disease outcomes. Most COVID-19 patients can recover at home with rest and over-the-counter symptom management.
The CDC advises seeking immediate medical attention if experiencing:
- Trouble breathing or persistent chest pain
- New confusion or inability to stay awake
- Bluish lips or facial discoloration
Individuals at higher risk due to age, underlying health conditions, or compromised immune systems should contact healthcare providers promptly after positive tests, as antiviral treatments may reduce hospitalization risks.
By February 11, 2026, BA.3.2 had been identified in at least 23 countries. Among these detections, four American travelers tested positive through the Traveler-based Genomic Surveillance program after returning from Japan, Kenya, the Netherlands, and the United Kingdom.
Two laboratory studies have indicated that BA.3.2 does not attach to human cells as efficiently as other variants, a limitation that may be slowing its transmission rate. Nevertheless, public health officials continue vigilant monitoring of this hyper-mutated strain as it establishes footholds across multiple regions.
